Radiation Countermeasure Agents: an Update (2011-2014)

Overview

Journal Expert Opin Ther Pat

Publisher Informa Healthcare

Date 2014 Oct 16

PMID 25315070

Citations 50

Authors

Vijay K Singh

Victoria L Newman

Patricia L P Romaine

Stephen Y Wise

Thomas M Seed

Affiliations

Soon will be listed here.

Abstract

Introduction: Despite significant scientific advances over the past 60 years towards the development of a safe, nontoxic and effective radiation countermeasure for the acute radiation syndrome (ARS), no drug has been approved by the US FDA. A radiation countermeasure to protect the population at large from the effects of lethal radiation exposure remains a significant unmet medical need of the US citizenry and, thus, has been recognized as a high priority area by the government.

Area Covered: This article reviews relevant publications and patents for recent developments and progress for potential ARS treatments in the area of radiation countermeasures. Emphasis is placed on the advanced development of existing agents since 2011 and new agents identified as radiation countermeasure for ARS during this period.

Expert Opinion: A number of promising radiation countermeasures are currently under development, seven of which have received US FDA investigational new drug status for clinical investigation. Four of these agents, CBLB502, Ex-RAD, HemaMax and OrbeShield, are progressing with large animal studies and clinical trials. G-CSF has high potential and well-documented therapeutic effects in countering myelosuppression and may receive full licensing approval by the US FDA in the future.

Citing Articles

Significant Reduction of Radiation-Induced Death in Mice Treated with PrC-210 and G-CSF after Irradiation.

Fahl W, Fahl B, Schult D, Goesch T Radiat Res. 2024; 202(4):662-669.

PMID: 39142656 PMC: 11528900. DOI: 10.1667/RADE-24-00102.1.

Cell Therapies for Acute Radiation Syndrome.

Christy B, Herzig M, Wu X, Mohammadipoor A, McDaniel J, Bynum J Int J Mol Sci. 2024; 25(13).

PMID: 39000080 PMC: 11241804. DOI: 10.3390/ijms25136973.

DAMPs and radiation injury.

Yamaga S, Aziz M, Murao A, Brenner M, Wang P Front Immunol. 2024; 15:1353990.

PMID: 38333215 PMC: 10850293. DOI: 10.3389/fimmu.2024.1353990.

Tocotrienols Provide Radioprotection to Multiple Organ Systems through Complementary Mechanisms of Antioxidant and Signaling Effects.

Shrum S, Nukala U, Shrimali S, Pineda E, Krager K, Thakkar S Antioxidants (Basel). 2023; 12(11).

PMID: 38001840 PMC: 10668991. DOI: 10.3390/antiox12111987.

Exosome-coated polydatin nanoparticles in the treatment of radiation-induced intestinal damage.

Chen Q, Yao L, Liu Q, Hou J, Qiu X, Chen M Aging (Albany NY). 2023; 15(14):6905-6920.

PMID: 37466428 PMC: 10415572. DOI: 10.18632/aging.204882.

References

Grace M, Singh V, Rhee J, Jackson 3rd W, Kao T, Whitnall M . 5-AED enhances survival of irradiated mice in a G-CSF-dependent manner, stimulates innate immune cell function, reduces radiation-induced DNA damage and induces genes that modulate cell cycle progression and apoptosis. J Radiat Res. 2012; 53(6):840-53. PMC: 3483857. DOI: 10.1093/jrr/rrs060. View

Farese A, Cohen M, Katz B, Smith C, Gibbs A, Cohen D . Filgrastim improves survival in lethally irradiated nonhuman primates. Radiat Res. 2012; 179(1):89-100. PMC: 4562422. DOI: 10.1667/RR3049.1. View

Augustine A, Gondre-Lewis T, McBride W, Miller L, Pellmar T, Rockwell S . Animal models for radiation injury, protection and therapy. Radiat Res. 2005; 164(1):100-9. DOI: 10.1667/rr3388. View

Basile L, Ellefson D, Gluzman-Poltorak Z, Junes-Gill K, Mar V, Mendonca S . HemaMax™, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates. PLoS One. 2012; 7(2):e30434. PMC: 3286478. DOI: 10.1371/journal.pone.0030434. View

Kma L, Gao F, Fish B, Moulder J, Jacobs E, Medhora M . Angiotensin converting enzyme inhibitors mitigate collagen synthesis induced by a single dose of radiation to the whole thorax. J Radiat Res. 2012; 53(1):10-7. PMC: 3616750. DOI: 10.1269/jrr.11035. View

Cohen E, Irving A, Drobyski W, Klein J, Passweg J, Talano J . Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial. Int J Radiat Oncol Biol Phys. 2007; 70(5):1546-51. PMC: 2386758. DOI: 10.1016/j.ijrobp.2007.08.041. View

Singh V, Wise S, Scott J, Romaine P, Newman V, Fatanmi O . Radioprotective efficacy of delta-tocotrienol, a vitamin E isoform, is mediated through granulocyte colony-stimulating factor. Life Sci. 2014; 98(2):113-22. DOI: 10.1016/j.lfs.2014.01.065. View

Monroy R, Skelly R, Taylor P, Dubois A, Donahue R, MacVittie T . Recovery from severe hematopoietic suppression using recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol. 1988; 16(5):344-8. View

Ma J, Hou Y, Han D, Zhang M, Chen C, Zhang B . Fibroblast growth factor-peptide promotes bone marrow recovery after irradiation. Adv Exp Med Biol. 2012; 765:155-161. DOI: 10.1007/978-1-4614-4989-8_22. View

10.

Chua H, Plett P, Sampson C, Katz B, Carnathan G, MacVittie T . Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors. Health Phys. 2013; 106(1):21-38. PMC: 3843155. DOI: 10.1097/HP.0b013e3182a4df10. View

11.

Singh V, Ducey E, Brown D, Whitnall M . A review of radiation countermeasure work ongoing at the Armed Forces Radiobiology Research Institute. Int J Radiat Biol. 2011; 88(4):296-310. DOI: 10.3109/09553002.2012.652726. View

12.

Schuening F, Appelbaum F, Deeg H, Graham T, Hackman R, Zsebo K . Effects of recombinant canine stem cell factor, a c-kit ligand, and recombinant granulocyte colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. Blood. 1993; 81(1):20-6. View

13.

Kiang J, Zhai M, Liao P, Bolduc D, Elliott T, Gorbunov N . Pegylated G-CSF inhibits blood cell depletion, increases platelets, blocks splenomegaly, and improves survival after whole-body ionizing irradiation but not after irradiation combined with burn. Oxid Med Cell Longev. 2014; 2014:481392. PMC: 3964894. DOI: 10.1155/2014/481392. View

14.

Reed G, Arneson D, Putnam W, Smith H, Gray J, Sullivan D . Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3'-diindolylmethane. Cancer Epidemiol Biomarkers Prev. 2006; 15(12):2477-81. DOI: 10.1158/1055-9965.EPI-06-0396. View

15.

Atkinson K, Matias C, Guiffre A, Seymour R, Cooley M, Biggs J . In vivo administration of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, interleukin-1 (IL-1), and IL-4, alone and in combination, after allogeneic murine hematopoietic stem cell transplantation. Blood. 1991; 77(6):1376-82. View

16.

Day R, Barshishat-Kupper M, Mog S, McCart E, Prasanna P, Davis T . Genistein protects against biomarkers of delayed lung sequelae in mice surviving high-dose total body irradiation. J Radiat Res. 2008; 49(4):361-72. PMC: 2575019. DOI: 10.1269/jrr.07121. View

17.

Williams J, Brown S, Georges G, Hauer-Jensen M, Hill R, Huser A . Animal models for medical countermeasures to radiation exposure. Radiat Res. 2010; 173(4):557-78. PMC: 3021126. DOI: 10.1667/RR1880.1. View

18.

Culy C, Spencer C . Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs. 2001; 61(5):641-84. DOI: 10.2165/00003495-200161050-00012. View

19.

Dumont F, Le Roux A, Bischoff P . Radiation countermeasure agents: an update. Expert Opin Ther Pat. 2009; 20(1):73-101. DOI: 10.1517/13543770903490429. View

20.

Seed T, Inal C, Singh V . Radioprotection of hematopoietic progenitors by low dose amifostine prophylaxis. Int J Radiat Biol. 2014; 90(7):594-604. PMC: 4133974. DOI: 10.3109/09553002.2014.899450. View